These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Impact of genetic and non-genetic factors on hepatic CYP2C9 expression and activity in Hungarian subjects. Fekete F; Mangó K; Déri M; Incze E; Minus A; Monostory K Sci Rep; 2021 Aug; 11(1):17081. PubMed ID: 34429480 [TBL] [Abstract][Full Text] [Related]
23. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Aithal GP; Day CP; Kesteven PJ; Daly AK Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515 [TBL] [Abstract][Full Text] [Related]
24. High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductase. Lee MY; Borgiani P; Johansson I; Oteri F; Mkrtchian S; Falconi M; Ingelman-Sundberg M Pharmacogenomics J; 2014 Aug; 14(4):343-9. PubMed ID: 24322786 [TBL] [Abstract][Full Text] [Related]
25. Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients. Thakkar AN; Bendkhale SR; Taur SR; Gogtay NJ; Thatte UM Neurol India; 2012; 60(6):577-80. PubMed ID: 23287317 [TBL] [Abstract][Full Text] [Related]
26. Structural and biophysical analysis of cytochrome P450 2C9*14 and *27 variants in complex with losartan. Parikh SJ; Edara S; Deodhar S; Singh AK; Maekawa K; Zhang Q; Glass KC; Shah MB J Inorg Biochem; 2024 Sep; 258():112622. PubMed ID: 38852293 [TBL] [Abstract][Full Text] [Related]
27. Cytochrome P450 2C9 polymorphism: Effect of amino acid substitutions on protein flexibility in the presence of tamoxifen. Manish M; Lynn AM; Mishra S Comput Biol Chem; 2020 Feb; 84():107166. PubMed ID: 31785970 [TBL] [Abstract][Full Text] [Related]
28. Insights into the Genetic Variations of Human Cytochrome P450 2C9: Structural Analysis, Characterization and Comparison. Parikh SJ; Kamat S; Phillips M; Boyson SP; Yarbrough T; Davie D; Zhang Q; Glass KC; Shah MB Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638547 [TBL] [Abstract][Full Text] [Related]
29. CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia. Ngow HA; Wan Khairina WM; Teh LK; Lee WL; Harun R; Ismail R; Salleh MZ Singapore Med J; 2009 May; 50(5):490-3. PubMed ID: 19495518 [TBL] [Abstract][Full Text] [Related]
30. The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations. Kirchheiner J; Tsahuridu M; Jabrane W; Roots I; Brockmöller J Per Med; 2004 Dec; 1(1):63-84. PubMed ID: 29793229 [TBL] [Abstract][Full Text] [Related]
31. Structural Basis of Single-Nucleotide Polymorphisms in Cytochrome P450 2C9. Maekawa K; Adachi M; Matsuzawa Y; Zhang Q; Kuroki R; Saito Y; Shah MB Biochemistry; 2017 Oct; 56(41):5476-5480. PubMed ID: 28972767 [TBL] [Abstract][Full Text] [Related]
33. Identification of the effects of pathogenic genetic variations of human Avsar O Nucleosides Nucleotides Nucleic Acids; 2024; 43(4):356-376. PubMed ID: 37747773 [TBL] [Abstract][Full Text] [Related]
34. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Ingelman-Sundberg M; Sim SC; Gomez A; Rodriguez-Antona C Pharmacol Ther; 2007 Dec; 116(3):496-526. PubMed ID: 18001838 [TBL] [Abstract][Full Text] [Related]
35. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Caudle KE; Rettie AE; Whirl-Carrillo M; Smith LH; Mintzer S; Lee MT; Klein TE; Callaghan JT; Clin Pharmacol Ther; 2014 Nov; 96(5):542-8. PubMed ID: 25099164 [TBL] [Abstract][Full Text] [Related]
36. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Zhou SF; Liu JP; Chowbay B Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967 [TBL] [Abstract][Full Text] [Related]
37. Insights into molecular mechanisms of drug metabolism dysfunction of human CYP2C9*30. Louet M; Labbé CM; Fagnen C; Aono CM; Homem-de-Mello P; Villoutreix BO; Miteva MA PLoS One; 2018; 13(5):e0197249. PubMed ID: 29746595 [TBL] [Abstract][Full Text] [Related]
38. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Theken KN; Lee CR; Gong L; Caudle KE; Formea CM; Gaedigk A; Klein TE; Agúndez JAG; Grosser T Clin Pharmacol Ther; 2020 Aug; 108(2):191-200. PubMed ID: 32189324 [TBL] [Abstract][Full Text] [Related]
39. Different inhibitory effects of azole-containing drugs and pesticides on CYP2C9 polymorphic forms: An in vitro study. Haidukevich IV; Sushko TA; Tumilovich AM; Grabovec IP; Usanov SA; Gilep AA Toxicol In Vitro; 2018 Aug; 50():249-256. PubMed ID: 29621561 [TBL] [Abstract][Full Text] [Related]
40. Enzymatic activity on valsartan of 38 CYP2C9 variants from the Chinese population. Yuan LJ; Qian JC; Li XY; Cui J; Cai JP; Hu GX Chem Biol Interact; 2022 Feb; 353():109799. PubMed ID: 34998819 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]